clinical trial · NCT03275103
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.·phase1·completed·n = 355
Multiple MyelomaCevostamabTocilizumab
brief summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
started
Sep 19, 2017
primary completion
Jan 7, 2026
completion
Jan 7, 2026
last updated
Feb 5, 2026
official title
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol